Knockdown of PREX2a inhibits the malignant phenotype of glioma cells.

Molecular Medicine Reports
Liang LiuShuai Wen

Abstract

Glioma is the most common type of malignant brain tumor. Phosphatidylinositol‑3,4,5‑trisphosphate‑dependent Rac exchange factor 2a (PREX2a), which is a regulator of the small guanosine triphosphatase Rac, has previously been identified as an oncoprotein that inhibits phosphatase and tensin homolog deleted on chromosome 10 (PTEN) activity. However, the role of PREX2a in the regulation of the malignant phenotype of glioma has yet to be reported. The present study demonstrated that the mRNA and protein expression levels of PREX2a were significantly increased in glioma tissue, as compared with in normal brain tissue. Furthermore, the expression levels of PREX2a were positively correlated with tumor grade. PREX2a‑specific small interfering RNA‑mediated knockdown significantly inhibited proliferation and induced apoptosis of SWO‑38 glioma cells. Furthermore, inhibition of PREX2a expression significantly suppressed cell cycle progression in glioma cells, as detected by cell cycle arrest at G1 phase. In addition, knockdown of PREX2a inhibited the invasion of SWO‑38 glioma cells. The present study also investigated the molecular mechanisms underlying the effects of PREX2a knockdown, and demonstrated that phosphoinositide 3‑kinase signal...Continue Reading

References

Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·B Kwabi-AddoM Ittmann
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jun 1, 2002·Science·Lewis C Cantley
Dec 24, 2003·PLoS Biology·Lloyd C TrotmanPier Paolo Pandolfi
Jun 15, 2004·The Biochemical Journal·Nick R Leslie, C Peter Downes
Aug 12, 2004·FEBS Letters·Hans RosenfeldtJ Silvio Gutkind
Aug 13, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kalevi J Pulkkanen, Seppo Yla-Herttuala
May 24, 2007·Cancer·Sith SathornsumeteeJeremy N Rich
Jul 10, 2007·Acta Neuropathologica·David N LouisPaul Kleihues
May 3, 2008·Cancer Research·Chang-Hyuk KwonLuis F Parada
May 6, 2008·Cell·Leonardo SalmenaPier Paolo Pandolfi
Sep 17, 2008·Oncogene·T L Yuan, L C Cantley
May 29, 2012·Advances in Experimental Medicine and Biology·Tomotoshi Marumoto, Hideyuki Saya
Sep 1, 2012·Current Molecular Medicine·B AuffingerM S Lesniak
Oct 4, 2012·Science Signaling·Laura Barrio-Real, Marcelo G Kazanietz
Dec 15, 2012·Cancer Genetics·McKinsey L Goodenberger, Robert B Jenkins
Jun 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Atanasio Pandiella, Juan Carlos Montero
Jan 1, 2014·Molecular Cancer Research : MCR·Bo GuoChen Huang
Oct 9, 2014·Frontiers in Oncology·Amancio Carnero, Jesus M Paramio
Dec 9, 2014·Advances in Biological Regulation·Matilde Y FolloLucio Cocco

❮ Previous
Next ❯

Citations

Jul 16, 2017·Biochemical Society Transactions·Nuthasuda SrijakotreChristina A Mitchell
Sep 29, 2020·Frontiers in Cell and Developmental Biology·Zeyu WangQuan Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis